These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24194959)

  • 1. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.
    Hedlund G; Eriksson H; Sundstedt A; Forsberg G; Jakobsen BK; Pumphrey N; Rödström K; Lindkvist-Petersson K; Björk P
    PLoS One; 2013; 8(10):e79082. PubMed ID: 24194959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
    Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
    J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
    Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
    Eisen T; Hedlund G; Forsberg G; Hawkins R
    Curr Oncol Rep; 2014 Feb; 16(2):370. PubMed ID: 24445502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
    Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
    Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
    Lando PA; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
    Immunology; 1993 Oct; 80(2):236-41. PubMed ID: 7505257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells.
    Ragnarsson L; Strömberg T; Wijdenes J; Tötterman TH; Weigelt C
    Cancer Immunol Immunother; 2001 Sep; 50(7):382-90. PubMed ID: 11676398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
    Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
    Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
    Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
    Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
    J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
    Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
    Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.
    Patterson KG; Dixon Pittaro JL; Bastedo PS; Hess DA; Haeryfar SM; McCormick JK
    PLoS One; 2014; 9(4):e95200. PubMed ID: 24736661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
    Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
    Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo.
    Rosendahl A; Hansson J; Antonsson P; Sékaly RP; Kalland T; Dohlsten M
    Infect Immun; 1997 Dec; 65(12):5118-24. PubMed ID: 9393804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.